You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雅本化學(300261.SZ):擬與Wundr設立一家醫用大麻的合資企業
格隆匯 12-17 15:50

格隆匯12月17日丨雅本化學(300261.SZ)公佈,為滿足公司戰略發展需要,公司全資子公司Amino Chemcials Limited(“ACL”)擬使用自有資金與Greenstar Global Inc.(Wundr Co.Wundr)馬耳他合資新設立A²W Pharma Limited(暫定名,A²W或“合資公司”)投資總額為600萬歐,其中ACL投資300萬歐元,佔註冊資本的50%

雙方特此成立一家合資企業,以研究開發製造和銷售醫用大麻以進行全球分銷,並作全球分銷——包括獲批必要的馬耳他當局的許可證

Wundr是一家總部位於倫敦的具有管制品資質的醫藥公司,致力於以最精確和有效的方式幫助歐洲患者和消費者,在整個醫用大麻供應鏈中具有深入的知識和專業知識。其全資子公司IUVO Therapeutics GmbH是擁有德國完全授權的GDP GMP藥品批發商,使其能夠在整個歐盟範圍內分銷售醫用大麻產品。

合資公司A²W主營業務:大麻二酚(“CBD”)等管制藥物的研發、生產和銷售CBD是藥用植物大麻中的主要化學成分,提取自雌性大麻植株,是大麻中的非成癮性成分,具有抗痙攣、抗焦慮、抗炎等藥理作用。201815日,馬耳他政府通過《藥用大麻生產法案》,允許醫用大麻產品生產合法化。

A²W將在馬耳他馬爾薩工業區設立新的大麻提取、加工工廠,確保按照GMP準則生產用於醫藥級的高質量CBD產品,研發大麻素類物質作為藥物活性成分的潛在用途及治療各種病症的新穎和創新的藥物製劑。

A²W工廠建設期約為10-12個月,建成達產後,預計第一年可實現淨利潤1250萬歐元,第二年可實現淨利潤2,500萬歐元。公司產品的目標市場包括歐洲及全球市場。

Wundr德國較早進行了整個醫用大麻供應鏈的佈局,在人力資源、技術開發及市場渠道等方面積累了較為豐富的經驗。此公司Wundr合作共同組建合資企業A²W從事醫用大麻產品的生產和銷售,將有利於快速介入醫用大麻等管制藥領域。

合資公司成立後,可將公司資金優勢、技術優勢與Wundr醫用大麻種植、加工技術相整合,疊加穩定的供應鏈及強大的銷售渠道,有助於迅速提升公司在管製藥物領域定製生產業務發展,形成優勢互補、合作共贏的良好局面,符合公司發展戰略;同時有利於拓寬公司原有的含左乙拉西坦、普拉克索、帕利哌酮等中樞神經藥品的產品線,打造新的利潤增長點,促進業績持續增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account